<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836641</url>
  </required_header>
  <id_info>
    <org_study_id>PAPSI.FFM.3217</org_study_id>
    <nct_id>NCT00836641</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics</brief_title>
  <acronym>PAPSI</acronym>
  <official_title>Prospective Randomized Controlled Phase 4 Study on the Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a major health problem in preschool children. Infections by pneumococci a the most
      frequent cause of airway infections, which tend to cause worsening of asthma. Vaccination
      against pneumococci is recommended by scientific boards and the medical community, in order
      to reduce the burden of disease. Data on the immunogenicity and safety of pneumococcal
      immunization in preschool asthmatics are scarce.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Respiratory infections are major triggers of exacerbations in preschool asthma. Many
      countries' guidelines recommend immunization against pneumococci for patients suffering from
      chronic airway disease. Also the interval between priming and booster is a matter of debate.

      We immunize a large group of preschool asthmatics (2-5 years old) sequentially: one dose of
      seven-valent pneumococcal conjugate vaccine (PCV-7) followed by a single dose of 23-valent
      pneumococcal polysaccharide vaccine (PPV-23). We randomly assign half of the vaccinees to
      receive PPV-23 eight weeks after PCV-7 (group A), and the rest to a 10-month interval (group
      B). Pneumococcal antibody concentrations to serotype 4, 5, 6B, 7, 9V, 14, 18c, 19F, and 23F
      are determined initially, after two, and 12 months after PCV-7. Local and systemic reactions
      to each vaccine are recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of Pneumococcal Vaccination</measure>
    <time_frame>12 months</time_frame>
    <description>we performed pneumococcal serotype specific ELISA according to WHO's criteria for protective threshold values (&gt;0.35 µg/ml).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Vaccinees With Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>we evaluated the safety and tolerability of sequential pneumococcal immunization as to local and systemic adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>pneumococcal immunization (2 mo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one dose of pneumococcal conjugate vaccine (prevenar) followed after 2 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pneumococcal immunization (10 mo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one dose of pneumococcal conjugate vaccine (prevenar) followed after 10 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>prevenar</intervention_name>
    <description>7-valent pneumococcal conjugate vaccine</description>
    <arm_group_label>pneumococcal immunization (2 mo)</arm_group_label>
    <arm_group_label>pneumococcal immunization (10 mo)</arm_group_label>
    <other_name>Prevnar, PCV-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pneumovax</intervention_name>
    <description>23 valent pneumococcal polysaccharide vaccine</description>
    <arm_group_label>pneumococcal immunization (2 mo)</arm_group_label>
    <arm_group_label>pneumococcal immunization (10 mo)</arm_group_label>
    <other_name>pneumopur, PPV-23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  asthma classified according to the Global Initiative on Asthma (GINA) °1-2

        Exclusion Criteria:

          -  antecedent pneumococcal immunization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University Childrens Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Rose MA, Schubert R, Kujumdshiev S, Kitz R, Zielen S. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma. Int J Clin Pract. 2006 Nov;60(11):1425-31.</citation>
    <PMID>17073839</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <results_first_submitted>April 4, 2013</results_first_submitted>
  <results_first_submitted_qc>July 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2013</results_first_posted>
  <last_update_submitted>July 30, 2013</last_update_submitted>
  <last_update_submitted_qc>July 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Markus Rose</investigator_full_name>
    <investigator_title>Professor of Paediatrics</investigator_title>
  </responsible_party>
  <keyword>preschool asthma</keyword>
  <keyword>sequential pneumococcal immunization</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>11/2005-09/07: 70 outpatients (2–5-yo)with &gt;3 asthma episodes during 12 months. Exclusion: pneumococcal immunization,severe/unstable asthma, systemic steroids, preterm birth (&lt;37 weeks of gestation), low birthweight (&lt;2500 g), major congenital abnormalities, and known intolerance towards ingredients of the pneumococcal vaccines.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Sequential Pneumococcal Immunzation (2 mo)</title>
          <description>one dose of pneumococcal conjugate vaccine followed after 2 months by one dose of pneumococcal polysaccharide vaccine</description>
        </group>
        <group group_id="P2">
          <title>Group B: Sequential Pneumococcal Immunization (10 mo)</title>
          <description>one dose of pneumococcal conjugate vaccine followed after 10 months by one dose of pneumococcal polysaccharide vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A Pneumococcal Immunization (2 mo)</title>
          <description>one dose of pneumococcal conjugate vaccine followed after 2 months by one dose of pneumococcal polysaccharide vaccine</description>
        </group>
        <group group_id="B2">
          <title>Group B Pneumococcal Immunization (10 mo)</title>
          <description>one dose of pneumococcal conjugate vaccine followed after 10 months by one dose of pneumococcal polysaccharide vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="0.5"/>
                    <measurement group_id="B2" value="3" spread="0.7"/>
                    <measurement group_id="B3" value="3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity of Pneumococcal Vaccination</title>
        <description>we performed pneumococcal serotype specific ELISA according to WHO's criteria for protective threshold values (&gt;0.35 µg/ml).</description>
        <time_frame>12 months</time_frame>
        <population>we performed a power calculation in advance. To demonstrate a difference wit p&lt;0.05, we would require 30 subjects per arm each. Thus and to allow potential drop-outs, we included 35 subjects per arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A Pneumococcal Immunization (2 mo)</title>
            <description>one dose of pneumococcal conjugate vaccine followed after 2 months by one dose of pneumococcal polysaccharide vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group B Pneumococcal Immunization (10 mo)</title>
            <description>one dose of pneumococcal conjugate vaccine followed after 10 months by one dose of pneumococcal polysaccharide vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of Pneumococcal Vaccination</title>
          <description>we performed pneumococcal serotype specific ELISA according to WHO's criteria for protective threshold values (&gt;0.35 µg/ml).</description>
          <population>we performed a power calculation in advance. To demonstrate a difference wit p&lt;0.05, we would require 30 subjects per arm each. Thus and to allow potential drop-outs, we included 35 subjects per arm.</population>
          <units>[µg/ml]</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.01" upper_limit="5.00"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.01" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Vaccinees With Adverse Events</title>
        <description>we evaluated the safety and tolerability of sequential pneumococcal immunization as to local and systemic adverse events.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A Pneumococcal Immunization (2 mo)</title>
            <description>one dose of pneumococcal conjugate vaccine followed after 2 months by one dose of pneumococcal polysaccharide vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group B Pneumococcal Immunization (10 mo)</title>
            <description>one dose of pneumococcal conjugate vaccine followed after 10 months by one dose of pneumococcal polysaccharide vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Vaccinees With Adverse Events</title>
          <description>we evaluated the safety and tolerability of sequential pneumococcal immunization as to local and systemic adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Overall Study Population</title>
          <description>the whole study population was observed for adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Markus Rose</name_or_title>
      <organization>Goethe University Childrens Hospital</organization>
      <phone>0049-696301 ext 5754</phone>
      <email>Markus.Rose@kgu.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

